Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022Phase 1 trial in…
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or the “Company”) (Nasdaq | TSX: TLRY),…
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease…
SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on…
EMERYVILLE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next…
RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers…
Libmeldy European launch momentum building with multiple MLD patients treated and strong recognition of value proposition; U.S. BLA filing of…
Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- Trevena,…
NERx innovations make leaps towards breast and lung cancer treatmentINDIANAPOLIS, March 30, 2022 (GLOBE NEWSWIRE) -- NERx Biosciences, an oncology…
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing…